Lasa Supergenerics Ltd
Pharmaceuticals & Biotechnology | Small Cap
Lasa Supergenerics Ltd, operating in the Healthcare Services sector, presents a mixed financial picture. The company demonstrates strengths in solvency, driven by a solid equity base. However, liquidity is a significant concern, with all ratios indicating poor short-term financial health. Growth metrics are volatile, with high operating profit and EPS growth offset by declines in asset and revenue growth. Coverage ratios are weak, reflecting challenges in meeting interest obligations. Profitability is also a concern, with low margins and returns. While the company shows positive trends in specific growth areas, the overall financial health is hampered by liquidity and profitability issues, suggesting potential risks for investors.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsHighly Undervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio5.20
- Financial Ratio4.00
- Profitability Ratio2.20
- Efficiency Ratio4.67
- Coverage Ratio2.00
- Solvency Ratio10.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentWeak
- Risk AssessmentWeak
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Lasa Supergenerics Ltd, operating in the Healthcare Services sector, presents a mixed financial picture. The company demonstrates strengths in solvency, driven by a solid equity base. However, liquidity is a significant concern, with all ratios indicating poor short-term financial health. Growth metrics are volatile, with high operating profit and EPS growth offset by declines in asset and revenue growth. Coverage ratios are weak, reflecting challenges in meeting interest obligations. Profitability is also a concern, with low margins and returns. While the company shows positive trends in specific growth areas, the overall financial health is hampered by liquidity and profitability issues, suggesting potential risks for investors.
Overall Valuation Score
P/E RATIO (TTM)
-1.16
Industry Median
23.93
Small Cap Median
23.93
P/E RATIO
-2.61
P/B RATIO
0.46
Industry Median
2.53
Small Cap Median
2.53
P/S RATIO
0.27
Industry Median
1.35
Small Cap Median
1.35
Others
PEG RATIO
0.10
EV/EBITDA RATIO
-9.41
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹7.7 as on Jun 15, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company's growth ratios show significant volatility. While operating profit and EPS growth rates are strong, revenue, asset, and net income growth rates are weak. This suggests that the company's profitability improvements may not be sustainable without broader growth across all areas. The healthcare industry's dynamic nature requires consistent growth in revenue and assets to maintain a competitive edge.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -31.84 | -5.11 | -20 | 36.54 | -82.39 |
| Operating Profit Growth Rate | -65.96 | -137.5 | -133.33 | 200 | -216.67 |
| Earnings Per Share (EPS) Growth | -123.39 | 488.55 | -43.71 | -32.03 | 130.51 |
| Asset Growth Rate | 0.48 | -21.53 | -7.93 | -32.45 | -35.29 |
| Net Income Growth Rate | -121.74 | 680 | -43.59 | -31.82 | 126.67 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The financial ratios reveal a mixed performance. While capital expenditures are well-managed, adjusted EPS, book value per share, and dividend per share are low. Cash EPS is moderate. This suggests challenges in generating consistent earnings and shareholder value. The healthcare sector's regulatory and competitive pressures can affect these ratios, requiring strategic financial management.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 0.6 | -4 | -2.8 | 0.2 | -2.6 |
| Cash Earnings Per Share (Cash EPS) | 2 | -5.2 | -2.2 | -0.6 | -5.6 |
| Book Value Per Share | 31.6 | 23.6 | 19.4 | 16.8 | 10 |
| Dividend Per Share (DPS) | 0.31 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 2.6 | 4.8 | 1.7 | 7.8 | 0.2 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios are generally weak. Gross profit margin, return on capital employed, return on equity, operating margin, and net margin are all low. Return on assets is slightly better but still below average. This suggests challenges in generating profits from its operations and assets. The healthcare industry's competitive pressures and regulatory environment may contribute to these challenges.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 0.73 | -14.62 | -8.65 | -4.23 | -52 |
| Return on Capital Employed (ROCE) | 1 | -12 | -6 | -1 | -18 |
| Return on Equity (ROE) | -3.16 | -33.05 | -22.68 | -17.86 | -68 |
| Return on Assets (ROA) | 7.66 | -3.66 | 1.32 | 5.88 | -10.61 |
| Operating Margin | 11.68 | -4.62 | 1.92 | 4.23 | -28 |
| Net Margin | -3.65 | -30 | -21.15 | -10.56 | -136 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios present a mixed picture. While days sales in inventory and receivable days are well-managed, turnover ratios for fixed assets, inventory, receivables, and capital are low. This suggests potential inefficiencies in asset utilization and working capital management. The healthcare industry's specific operational demands may influence these ratios, but improvements in asset turnover could enhance overall efficiency.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1 | 1.09 | 0.95 | 2.09 | 0.45 |
| Inventory Turnover Ratio | 9.39 | 11.73 | 6.86 | 6.8 | 2.89 |
| Receivables Turnover Ratio | 8.22 | 12.36 | 34.27 | 55.91 | 32.68 |
| Days Sales in Inventory Ratio | 38.87 | 31.12 | 53.21 | 53.68 | 126.3 |
| Receivable Days | 44.4 | 29.53 | 10.65 | 6.53 | 11.17 |
| Capital Turnover Ratio | 0.77 | 1.1 | 1.07 | 1.69 | 0.5 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios are weak, particularly concerning the interest coverage ratio. This indicates potential difficulties in meeting interest obligations, which could increase financial risk. The healthcare industry's capital-intensive nature requires careful management of debt and interest expenses to ensure financial stability.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | N/A | -9.5 | -8.5 | -5.33 | N/A |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency position is strong, primarily due to a high equity ratio and low debt levels. This indicates a solid financial foundation and lower risk of financial distress. The company's reliance on equity rather than debt provides stability and resilience. However, it's important to monitor whether this capital structure supports optimal growth and profitability in the long term.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.11 | 0 | 0 | 0 | 0 |
| Debt to Equity Ratio | 0.12 | 0 | 0 | 0 | 0 |
| Equity Ratio | 0.89 | 1 | 1 | 1 | 1 |
| Debt To Asset Ratio | 0.1 | 0 | 0 | 0 | 0 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is weak, with all liquidity ratios indicating poor short-term financial health. This suggests potential difficulties in meeting immediate obligations and managing working capital. The lack of liquid assets may hinder operational flexibility and increase financial risk. While the healthcare industry can have unique working capital cycles, these ratios raise concerns about the company's ability to handle unforeseen expenses or invest in growth opportunities.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 2.16 | 0.87 | 0.72 | 1.82 | 0.66 |
| Quick Ratio | 1.79 | 0.57 | 0.37 | 0.47 | 0.55 |
| Cash Ratio | 0.56 | 0.05 | 0.03 | 0.04 | 0.04 |
| Operating Cash Flow Ratio | 0.29 | -0.37 | 0.04 | -0.17 | 0 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medicamen Organics Ltd | 6.30 | -6.94 | Neutral | -3.75 | -2.50 | -4.02 |
| 2 | Mono Pharmacare Ltd | 6.16 | 6.26 | Neutral | 8.00 | 1.75 | 3.00 |
| 3 | JFL Life Sciences Ltd | 6.07 | 9.43 | Neutral | 12.00 | 1.94 | 6.00 |
| 4 | Walpar Nutritions Ltd | 5.29 | 9.26 | Neutral | 6.66 | 2.09 | 3.00 |
| 5 | Mangalam Drugs and Organics Ltd | 4.50 | -1.07 | Neutral | -15.00 | -27.68 | -44.00 |
| 6 | Lasa Supergenerics Ltd | 4.39 | -2.61 | Highly Undervalued | -7.00 | -6.80 | -34.00 |
The management effectiveness of Lasa Supergenerics Ltd appears weak based on the available data due to negative profit, returns on equity, and inconsistent financial performance. The company has experienced fluctuating sales growth and negative profit margins, indicating operational inefficiencies. Despite an increase in promoter holding, the overall financial performance raises concerns about the management's effectiveness in driving sustainable growth and profitability.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 53.65% | Indicates promoter confidence. |
| CONS | ROCE | -13.23% | Suggests inefficient capital utilization. |
| ROE | -20.22% | Indicates poor return to shareholders. | |
| Dividend Payout % | 0.00 % | Indicates company is not sharing profits with shareholders. |
Financial Performance & Growth
Lasa Supergenerics exhibits inconsistent financial performance and growth. Sales have been volatile. The operating profit margin has fluctuated significantly, with negative values observed in multiple quarters. Net profit has also been negative in recent periods, indicating challenges in achieving sustained profitability.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Sales | 137 | 130 | 104 | 142 |
| Operating Profit | 16 | -6 | 2 | 6 |
| Net Profit | -5 | -39 | -22 | -15 |
Capital Efficiency & Returns
Capital efficiency and returns for Lasa Supergenerics are concerning. The Return on Capital Employed (ROCE) is negative, indicating inefficient use of capital. Return on Equity (ROE) is also negative, showing poor returns to shareholders.
| Metric | Mar 2017 | Mar 2019 | Mar 2021 | Mar 2023 | Mar 2025 |
|---|---|---|---|---|---|
| ROCE % | 42% | -4% | 17% | -12% | -1% |
Financial Health & Prudence
The financial health of Lasa Supergenerics raises concerns due to its debt management and interest coverage. Although borrowings have decreased significantly in the most recent year, the company's history shows reliance on debt. The absence of dividend payouts further underscores financial constraints.
| Metric | Mar 2018 | Mar 2020 | Mar 2022 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Borrowings | 107 | 48 | 20 | 22 | 2 |
| Dividend Payout % | 0% | 0% | -24% | 0% | 0% |
Strategic & Operational Indicators
Lasa Supergenerics' strategic and operational indicators present a mixed picture. Working capital management, as indicated by the cash conversion cycle, has fluctuated.
| Metric | Mar 2019 | Mar 2021 | Mar 2023 | Mar 2025 |
|---|---|---|---|---|
| Cash Conversion Cycle | -18 | 42 | 22 | 53 |
The risk assessment for Lasa Supergenerics Ltd indicates a high level of risk due to negative profitability, inconsistent sales growth, and negative returns on capital employed and equity. The volatility in quarterly sales and profit growth, combined with fluctuating operating profit margins, suggests instability. The decreased borrowings may indicate improved debt management but the overall financial health remains weak.
Accounting quality red flags
There is no specific data available regarding off-balance sheet exposure quantification, contingent liability evaluation
Segment performance volatility
There is no specific data available to evaluate the segment performance volatility.
Foreign exchange or interest rate exposure
There is no specific data available to evaluate the foreign exchange or interest rate exposure.
Regulatory compliance cost trends
There is no specific data available to evaluate the regulatory compliance cost trends.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe